This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Novartis says top French court annulled its antitrust victory in Lucentis case (correct*)

( July 18, 2025, 07:31 GMT | Official Statement) -- MLex Summary: Novartis said it may need to pay an antitrust fine of $443 million after France's top court sided with the French Competition Authority in a landmark case over its Lucentis eyesight treatment. At the heart of the litigation is a 2019 finding that Novartis and Roche abused a dominant position by denigrating or trash-talking a rival, Avastin. A lower-court, which originally upheld Novartis's appeal, has been ordered to re-examine the case.  *Corrected on July 18, 2025 at 13:43 GMT: Novartis’s provision for the fine is in dollars, not euros.The relevant part of Novartis's filing to US Securities and Exchange Commission follows....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections